Projet HER-CARE (Horizon Europe, appel à projets 2024)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

Breast cancer is the most frequently diagnosed cancer in women, with European countries having some of the highest age-standardized incident rates of early-onset (< age 50) breast cancer in the world. Yet, our understanding of the genetic and environmental factors triggering the pathophysiology of the disease in young women is still limited. Advancing breast cancer prevention and treatment demands a holistic approach towards an accurate and early tumour detection – strongly linked with better clinical outcomes. HER-CARE aims to revolutionize the approach to hereditary and early-onset breast cancer through an innovative, interdisciplinary research and training program. The project will address critical gaps in early detection, risk stratification, and clinical management by developing tools that integrate genetic, molecular, and imaging data with state-of-the-art technologies, including artificial intelligence, machine learning, and advanced statistical modelling. These efforts will uncover: i) new molecular mechanisms and biological targets that can be targeted in hereditary and early-onset breast cancer; ii) better multifactorial risk profiles to enhance prediction accuracy; iii) new minimally invasive tools and assays to detect and intercept breast cancer early. The resulting tools and methodologies will: enhance early detection with accessible, personalized treatment and preventative strategies tailored to young women; ii) improve genetic counselling and clinical management; iii) improve treatment guidelines/ cancer prevention programs; and iv) reduce the high rate of misdiagnoses and overtreatment. HER-CARE will train the next generation of researchers by equipping 15 Doctoral Candidates with multidisciplinary skills spanning genetics, bioinformatics, molecular biology, cancer epidemiology, biostatistics, and computational science to transform the management of hereditary and early-onset breast cancer.

Mots clés : breast cancer, early onset cancer, young women, risk stratification, artificial intelligence, machine learning, personalized medicine, cancer detection, statistical modeling, precision oncology

Participants :
- Methylomics b.v. (Pays-Bas) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université du Danemark du Sud (Danemark) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Antoni van Leeuwenhoekziekenhuis (Pays-Bas) — Coordinator, beneficiary, Recherche, subvention : 915857.28 €
- Stremble ventures ltd (Chypre) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Institut Karolinska (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 324630.0 €
- Oxford Nanopore Technologies (United Kingdom) (Royaume-Uni) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Radboud University Medical Centre (Pays-Bas) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Leiden University Medical Center (Pays-Bas) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Consorcio para la explotacion del centro nacional de analisis genomico (Espagne) — Partner, beneficiary, Recherche, subvention : 282188.16 €
- QIMR Berghofer Medical Research Institute (Australie) — Partner, associated partner, Autres, subvention : 0.0 €
- Foundation for genomics & population health (Royaume-Uni) — Partner, associated partner, Recherche, subvention : 0.0 €
- Université de Barcelone (Espagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université Johns-Hopkins (Etats-Unis) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université d'Utrecht (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 305285.76 €
- Institut Gustave Roussy (France) — Partner, beneficiary, Recherche, subvention : 314669.16 €
- Icad, inc (Etats-Unis) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université de médecine de Vienne (Autriche) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 605085.84 €
- AstraZeneca (United Kingdom) (Royaume-Uni) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University Hospital Cologne (Allemagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Region of Southern Denmark (Danemark) — Partner, beneficiary, Organismes publics (hors enseignement & recherche), subvention : 335890.08 €
- Université d'Oxford (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Proteotype diagnostics ltd (Royaume-Uni) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 348738.12 €
- Université Paris-Saclay (France) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Veracyte, inc. (Etats-Unis) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Evidencio bv (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 305285.76 €
- Siemens Healthcare (Germany) (Allemagne) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université de Twente (Pays-Bas) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université Masaryk (Rép. Tchèque) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Institut chypriote de neurologie et de génétique (Chypre) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 262410.84 €
- Institute of Cancer Research (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 348738.12 €
- Université de Cambridge (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 348738.12 €
- Sophia genetics sa (Suisse) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Dutch Cancer Society (Pays-Bas) — Partner, associated partner, Autres, subvention : 0.0 €